Gas SF6 (Sulfur Hexafluoride)

PreclinicalSmall molecule

Gas SF6 (Sulfur Hexafluoride) is one of 7 small molecule programs targeting Keratoconus. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KeratoconusActive, not recruiting

KeratoconusPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Keratoconus

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

1 2

Mitosol

UUroGen Pharma Ltd.

Approved

—3

Decadron

AAspen Global Incorporated

Neoral

Botox

RRevance Therapeutics, Inc.

Preclinical

1 6

Cyclosporins

Merck & Co.

Preclinical

1 7

Gas SF6 (Sulfur Hexafluoride)

HHaEmek Medical Center, Israel

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Keratoconus1 trial

Intracameral Gas SF6 (Sulfur Hexafluoride) Injection for Acute Hydrops in Keratoconus

Completed·HHaEmek Medical Center, Israel·N/A·NCT00593190·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gas SF6 (Sulfur Hexafluoride). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gas SF6 (Sulfur Hexafluoride) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gas SF6 (Sulfur Hexafluoride). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HaEmek Medical Center, Israel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHaEmek Medical Center, Israel

Gas SF6 (Sulfur Hexafluoride)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Keratoconus1 trial

References

Drug Info

Quick Facts

Related News